Revenue, 2025

USD 169.27 Million

Forecast, 2035

USD 841.9 Million

CAGR, 2026-2035

17.4%

Report Coverage

Global

Blood-Based Biomarker for Alzheimer’s Disease Diagnostics Market Trends for 2026

The global blood-based biomarker for Alzheimer’s disease diagnostics market size was estimated at USD 169.27 million in 2025 and is predicted to increase from USD 198.72 million in 2026 to approximately USD 841.9 million by 2035, expanding at a CAGR of 17.4% from 2026 to 2035. The growing incidence of Alzheimer’s disease is increasing the use of blood-based biomarkers. The growing R&D activities, government support, and launch of new products are also enhancing the market growth.

Key Takeaways

• The blood-based biomarker for Alzheimer’s disease diagnostics market will likely exceed USD 198.72 million by 2026.
• Valuation is projected to hit USD 841.9 million by 2035.
• Estimated to grow at a CAGR of 17.4% starting from 2026 to 2035.
• North America held the major revenue share of 40% in the global blood-based biomarker for Alzheimer’s disease diagnostics market in 2025.
• Asia Pacific held a share of 20% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By biomarker type, the tau-based biomarkers segment dominated the market with 40% share in 2025 and is expected to grow with the fastest CAGR during the forecast period.
• By technology platform type, the immunoassays segment held a dominant revenue share of 45% of the market in 2025.
• By technology platform type, the mass spectrometry segment held 25% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.
• By application type, the early detection/screening segment held a dominant revenue share of 30% of the market in 2025 and is expected to grow with the fastest CAGR during the forecast period.
• By end user, the hospitals segment held a dominant position in the market with a share of 35% in 2025.
• By end user, the point-of-case settings segment held 8% of market share in 2025 and is expected to grow at the fastest CAGR during the forecast period.

What is the Blood-Based Biomarker for Alzheimer’s Disease Diagnostics?

The blood-based biomarker for Alzheimer’s disease diagnostics market is driven by growing demand for non-invasive screening, expanding new therapies, and regulatory breakthroughs. The blood-based biomarker for Alzheimer’s disease diagnostics refers to the molecules measured in blood indicating the presence, risk, and progression of Alzheimer’s disease. They help in early disease detection, disease monitoring, diagnosis confirmation, and support drug development.

What is the Use of AI in the Market?

The use of AI in the blood-based biomarker for Alzheimer’s disease diagnostics market is increasing as it helps in the detection of biomarker changes, leading to an early detection of Alzheimer's disease. It also helps in predicting disease onset and high-risk individuals, where it also helps in integrating multiple biomarkers, enhancing the diagnostic accuracy. It also offers automated interpretation, disease progression monitoring, drug development, and clinical trials as well.

What are the Trends & Future Outlook of the Market?

Expanding Applications

The growing blood-based biomarker for Alzheimer’s disease diagnostics applications are driving their adoption in detection and diagnosis. They are being used for therapeutic monitoring, the development of precision medication, and clinical trial applications.

Growing Approvals

A rise in the blood-based biomarker for Alzheimer’s disease diagnostics approval rates is increasing their adoption across healthcare settings, as well as creating new opportunities for the development of new high-sensitivity, specific, and portable diagnostics.

Technological Innovations

The growing technological advancements are promoting the development of ultra-sensitive assay platforms, multiplex panels, digital tools, and next-generation technologies to enhance the blood-based biomarker for Alzheimer’s disease diagnostics applications.

Key Indicators and Highlights

Segmental Insights

By Biomarker Type Insights

The Tau-Based Biomarkers Segment Dominated the Market in 2025

The tau-based biomarkers segment led the blood-based biomarker for Alzheimer’s disease diagnostics market with 40% share in 2025 and is expected to grow with the fastest CAGR during the forecast period, due to a growth in the early Alzheimer’s disease pathology detection. Their high specificity also increased their use. The strong correlation between brain changes and enhanced diagnostic accuracy also increased their use.

The amyloid-based biomarkers segment held the second-largest share of 35% in 2025, driven by their high diagnostic accuracy. They also help in the early detection of Alzheimer’s disease before the onset of clinical symptoms. The growing technological advancements are also increasing their innovation and use as a screening tool.

The neurodegeneration biomarkers segment held 15% share of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, due to their ability to reflect neuronal damage progression. This helps in the early detection of neurodegeneration and disease progression. Growing brain disorders are also increasing their demand.

The inflammatory biomarkers segment held 5% share of the market in 2025, driven by their growing application in linking the neuroinflammation to Alzheimer’s disease. The growing advancements in the anti-inflammation and immunomodulatory treatment are also increasing their use. It is also being used in the detection of disease progression, where its growing integration with other biomarkers is increasing its innovations.

By Technology Platform Insights

The Immunoassays Segment Dominated the Market in 2025

The immunoassays segment held the dominating share of 45% of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, driven by their affordable scalability. Their high sensitivity and specificity also increased their use. Additionally, their easy use, high-throughput screening, and widespread availability also increased their use.

The mass spectrometry segment held the second-largest share of 25% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to its high sensitivity detection. Their ultra-high analytical accuracy is also increasing their adoption rates. Additionally, the simultaneous detection of multiple biomarkers is also increasing their demand.

The biosensor-based platforms segment held 12% share of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, driven by their rapid point-of-care testing. Their high sensitivity and real-time detection also increased their use. Furthermore, their compact sizes and multiplexing potential are also increasing their adoption rates.

The PCR-based assays segment held 10% share of the market in 2025, due to their growing use in genetic correlation studies. Their high sensitivity and security are also increasing their use in the early detection of Alzheimer’s disease. The multiplexing ability and requirement of minimal sample volume are also increasing their demand.

By Application Insights

The Early Detection/Screening Segment Dominated the Market in 2025

The early detection/screening segment registered its dominance over the global blood-based biomarker for Alzheimer’s disease diagnostics market with a share of 30% in 2025 and is expected to grow with the fastest CAGR during the forecast period, due to growth in the demand for preventive healthcare. The growth in Alzheimer’s cases also increased the use of blood-based biomarker diagnostics. Additionally, their non-invasive approach and affordability also increased their use.

The diagnosis confirmation segment held the second-largest share of 25% of the market in 2025, driven by its increasing use in clinical decision-making. Their high accuracy and rapid results are also increasing their adoption rates. Moreover, their growing integration with multi-modal diagnostics is also increasing their demand.

The drug development & clinical trials segment held 20% share of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, as the blood-based biomarker for Alzheimer’s disease diagnostics helps in accelerating the biomarker-based clinical trials. It also helps in the early patient selection and recruitment. They also help in the development of precision medicines.

The disease monitoring segment held 15% share of the market in 2025, driven by the ability to track the disease progression. The blood-based biomarker for Alzheimer’s disease diagnostics also helps in the detection of treatment failure and support disease modifying therapies. It also helps in adjusting the drug dose, depending on the patient's response.

By End User Insights

The Hospitals Segment Dominated the Market in 2025

The hospitals segment held the largest share of 35% of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, due to growth in the patient volume. This increased the clinical application of the blood-based biomarker for Alzheimer’s disease diagnostics. The presence of well-equipped infrastructure and skilled professionals also increased patient trust, which contributed to their increased use.

The diagnostic laboratories segment held the second-largest share of 30% of the market in 2025 and is expected to grow at the fastest CAGR during the forecast period, driven by the expanding testing infrastructure. Moreover, the adoption of high technologies is also increasing the use of new blood-based biomarkers for Alzheimer’s disease diagnostics. Their affordable operation are also attracting the patients.

The research institutes segment held 15% share of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025, due to growing biomarker innovations. The advancements in multiplex studies and focus on early disease detection technologies are also increasing the use of blood-based biomarkers for Alzheimer’s disease diagnostics. Additionally, increasing funding is also accelerating their innovations.

The pharmaceutical & biotechnology companies segment held 12% share of the market in 2025, due to growing clinical trials and drug development. The growing advancements in precision medicine and companion diagnostics are also increasing the use of blood-based biomarkers for Alzheimer’s disease diagnostics. The growing partnerships are also increasing their innovations and use.

The point-of-care setting held 8% of the market share in 2025 and is estimated to be the fastest-growing during the forecast period because it enables rapid decentralized testing, leading to quicker and better results.

Regional Insights

Advanced Technology Adoption Drives North America

North America dominated the blood-based biomarker for Alzheimer’s disease diagnostics market with 40% in 2025, due to growth in the adoption of advanced diagnostics, where the rise in Alzheimer's disease also increased the use of blood-based biomarkers for Alzheimer’s disease diagnostics. The growth in healthcare spending and R&D activities also increased their innovation, which contributed to the market growth.

U.S. Market Trends

The growing incidence of Alzheimer’s disease in the U.S. is increasing the demand for blood-based biomarkers for Alzheimer’s disease diagnostics. The presence of advanced healthcare infrastructure is also increasing their adoption rates. Moreover, the growing clinical trials, healthcare investments, and technological advancements are also increasing their innovations.

Growth in the Geriatric Population Boost Asia Pacific

Asia Pacific held a share of 20% of the blood-based biomarker for Alzheimer’s disease diagnostics market in 2025 and is expected to grow at the fastest CAGR during the forecast period, due to growth in the geriatric population. The rise in disease awareness is also increasing the adoption of blood-based diagnostics. Expanding healthcare is also increasing its use, enhancing the market growth.

India Market Trends

The rapid expansion of healthcare in India is increasing the adoption of the blood-based biomarker for Alzheimer’s disease diagnostics in India. A growing geriatric population and increasing government initiatives are also increasing their use. Additionally, growing R&D activities and health awareness are also increasing their innovations and adoption rates.

Market Value Chain Analysis

R&D

• The R&D of the blood-based biomarker for Alzheimer’s disease diagnostics focuses on ultrasensitive p-tau217 and neurofilament light (MfL) assay development.
• Key players: Roche Diagnostics, Quanterix, Eli Lilly & Co.

Clinical Trials and Regulatory Approvals

• The diagnostic accuracy is evaluated in the clinical trials and regulatory approvals of the blood-based biomarker for Alzheimer’s disease diagnostics to promote its use for treatment monitoring, patient enrichment, and target engagement.
• Key players: Roche Diagnostics, Eli Lilly & Co.

Patient Support and Services

• The blood collection networks, financial assistance programs, and online portal are provided in the patient support and services of the blood-based biomarker for Alzheimer’s disease diagnostics.
• Key players: Quest Diagnostics, Labcorp.

Who are the Market Top Vendors and What are Their Offerings?

SWOT Analysis

Strengths

• The blood-based biomarker for Alzheimer’s disease diagnostics offers a minimally invasive approach, which increases its adoption rates.
• Their affordability also enhances their accessibility, increasing their acceptance rates.
• They also help in early and acute detection of Alzheimer’s disease, driving their adoption rates.
• It is also being used for the monitoring of the disease progression.

Weaknesses

• The lower specificity acts as the major weakness in the blood-based biomarker for Alzheimer’s disease diagnostics market, which limits its use.
• False positive results and standardization issues also reduce their use.

Opportunities

• The growing health awareness is increasing the use of blood-based biomarkers for Alzheimer’s disease diagnostics for the early detection of the disease.
• Growing advancements in personalized medicine are also increasing their use.
• Expanding routine check-ups are also increasing their adoption rates.
• Increasing technological advancements are also increasing the adoption of advanced tools, driving their innovations.

Threats

• Inconsistency due to assay variability leading to the batch failure limits their innovations.
• Stringent quality control and regulatory standards also slow down their innovations.

Recent Developments in the Market

• In March 2026, an affordable and non-invasive simple blood test leveraging p-tau and amyloid protein for the early detection of Alzheimer’s disease, titled Mispa i60, was launched by Neuberg Diagnostics.
• In March 2026, the third phase of the Diagnostics Accelerator (DxA) developed by Alzheimer's Drug Discovery Foundation (ADDF) was announced, where it also received an additional $50 million in funding, which will support the development of next-generation biomarkers, accelerating drug development, combination therapies, and precision medicine for Alzheimer's patients.

Segments Covered in the Report

By Biomarker Type

• Amyloid-Based Biomarkers
• Tau-Based Biomarkers
• Neurodegeneration Biomarkers
• Inflammatory Biomarkers
• Other Emerging Biomarkers

By Technology Platform

• Immunoassays
• Mass Spectrometry
• PCR-Based Assays
• Next-Generation Sequencing
• Biosensor-Based Platforms

By Application

• Early Detection/Screening
• Diagnosis Confirmation
• Disease Monitoring
• Drug Development & Clinical Trials
• Risk Assessment/Predictive Testing

By End User

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Pharmaceutical & Biotechnology Companies
• Point-of-Care Settings

By Test Type

• Laboratory-Based Tests 
• Point-of-Care Tests

By Sample Type

• Plasma 
• Serum
• Whole Blood

By Distribution Channel 

• Direct Sales
• Distributors
• Online Platforms

By Region

• North America
  • U.S.
  • Canada 
  • Mexico 
  • Rest of North America
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America
• Europe 
  • Western Europe 
    • Germany 
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal 
    • Belgium
    • Ireland
    • UK 
    • Iceland 
    • Switzerland
    • Poland
    • Rest of Western Europe
  • Eastern Europe 
    • Austria
    • Russia & Belarus 
    • Türkiye
    • Albania 
    • Rest of Eastern Europe 
• Asia Pacific
  • China 
  • Taiwan
  • India 
  • Japan 
  • Australia and New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea 
  • Rest of APAC 
• MEA 
  • GCC Countries
    • Saudi Arabia 
    • United Arab Emirates (UAE)
    • Qatar 
    • Kuwait 
    • Oman 
    • Bahrain 
  • South Africa
  • Egypt 
  • Rest of MEA